HomeIndustriesHealthcareModerna (MRNA) Could Struggle This Year & Outlook For Weight Loss Drugs

Moderna (MRNA) Could Struggle This Year & Outlook For Weight Loss Drugs

We expect Moderna (MRNA) to launch multiple products in 2025, notes Lee Brown. He discusses vaccine stocks in focus. He talks about how MRNA posts a wider loss and cuts guidance as Covid vaccine sales drop. Brown also goes over how new RSV and flu vaccines are expected from MRNA. He expects MRNA to struggle to compete this year with GSK and PFE. He then looks at the outlook for weight loss drugs, highlighting Eli Lilly (LLY). Tune in to find out more about the stock market today.

Morning Trade Live

02 Nov 2023

SHARE

ON AIR
12:30 am
Market On Close
replay
12:00 am
Market Overtime
REPLAY
ON AIR
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor